85–90% of non-Hodgkin lymphoma cases are B-cell non-Hodgkin lymphoma (NHL). It is a cancer that develops from abnormal B lymphocytes and is caused by DNA mutations that disrupt cellular regulation, leading to uncontrolled growth. Common subtypes include diffuse large B-cell lymphoma (DLBCL, 33% of cases), follicular lymphoma, and mantle cell lymphoma. Treatment varies depending on the aggressiveness of the disease; aggressive types like DLBCL use chemotherapy (e.g., R-CHOP regimen) or radiation treatment. Risk factors include immune disorders and viral infections. The B cell non-Hodgkin lymphoma pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the B cell non-Hodgkin lymphoma pipeline analysis include Hoffmann-La Roche, Novartis Pharmaceuticals, and Merck Sharp & Dohme LLC among others.
Leading drugs currently in the pipeline include glofitamab, tisagenlecleucel, and others.
Advancements in novel antiviral therapies and immune-modulating agents are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into B cell non-Hodgkin lymphoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for B cell non-Hodgkin lymphoma. The B cell non-Hodgkin lymphoma report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The B cell non-Hodgkin lymphoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with B cell non-Hodgkin lymphoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to B cell non-Hodgkin lymphoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
B-cell non-Hodgkin lymphoma (B-NHL) develops in mature B-cells with genetic and epigenetic abnormalities. It is often involving dysregulated signaling pathways. Mutations in BCL6, BCL2, and MYC are important oncogenic drivers for the condition as they inhibit apoptosis and encourage unchecked proliferation. NF-κB is a vital survival pathway that is activated by persistent B-cell receptor (BCR) activation.
The course of treatment for B-cell non-Hodgkin lymphoma (B-NHL) depends on the patient's health, stage, and disease subtype. For aggressive types like diffuse large B-cell lymphoma (DLBCL), standard treatments include chemotherapy regimens such as R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone). Targeted medications like ibrutinib are used to block pathways that promote cell proliferation, whereas immunotherapy using monoclonal antibodies (such as rituximab) improves the targeting of cancerous cells. Stem cell transplants are saved for instances that have relapsed or are resistant, while radiation treats circumscribed cancers. Refractory illness may benefit from new CAR T-cell therapy. While late cases of indolent lymphomas require systemic treatment, early-stage cases may merely need to be monitored. Although the prognosis varies, frontline therapy for DLBCL has a 60–70% cure rate.
With 85% of cases, B-cell non-Hodgkin lymphoma (B-NHL) is the most prevalent form of NHL. B-NHL is more common in men and older people, and NHL accounts for around 3% of cancer diagnoses and deaths worldwide. NHL accounts for 4% of all malignancies in the United States, and an estimated 80,350 additional cases are anticipated in 2025. Since 2015, incidence rates have decreased by 1% yearly, while therapeutic improvements have greatly increased survival.
This section of the report covers the analysis of B cell non-Hodgkin lymphoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total B cell non-Hodgkin lymphoma clinical trials.
In the B cell non-Hodgkin lymphoma pipeline, nearly equal number of candidates are in Phase II and Phase I with 46% and 44% of the projects respectively followed by just 10% of projects in Phase III. Thus, demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the B cell non-Hodgkin lymphoma pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The B cell non-Hodgkin lymphoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for B cell non-Hodgkin lymphoma.
The EMR report for the B cell non-Hodgkin lymphoma pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in B cell non-Hodgkin lymphoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for B cell non-Hodgkin lymphoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of B cell non-Hodgkin lymphoma drug candidates.
Glofitamab, developed by Hoffmann-La Roche, is a bispecific monoclonal antibody designed to treat B-cell non-Hodgkin lymphomas, including diffuse large B-cell lymphoma (DLBCL). Currently in late Phase 1 clinical trials, it targets CD20 on B-cells and CD3 on T-cells, activating T-cells to destroy malignant B-cells. In studies, it achieved a 56% overall response rate, with cytokine release syndrome as the most common adverse event.
Tisagenlecleucel, marketed as Kymriah by Novartis Pharmaceuticals, is a chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory B-cell malignancies, including non-Hodgkin lymphoma. Currently in Phase 3 clinical trials, it modifies a patient’s T-cells to target CD19-expressing cancer cells. In the JULIET trial, it achieved a 52% overall response rate. Common side effects include cytokine release syndrome and neurological events.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The B Cell Non-Hodgkin Lymphoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for B cell non-Hodgkin lymphoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into B cell non-Hodgkin lymphoma collaborations, regulatory environments, and potential growth opportunities.
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share